HonorHealth Scottsdale Osborn Medical Center receives Comprehensive Stroke Center Certification prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
MOUNTAIN VIEW, Calif., Jan. 19, 2021 /PRNewswire/ BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced today the initiation of patient enrollment at the HonorHealth Research Institute in Scottsdale, Ariz. for a Phase 1 dose-escalation trial to treat refractory solid tumors. The trial marks the first-in-human study of CRX100, an intravenously delivered agent designed to target and destroy multiple cancer types and address disease recurrence. We are excited to be working with HonorHealth as we advance CRX100 into the clinic, an event that marks a major milestone for our company, stated Pamela Contag, Ph.D., President and CEO of BioEclipse. CRX100 is a single therapeutic designed to attack multiple characteristics of numerous cancer types. With this new approach, BioEclipse is poised to address the substantial